SG10202010389TA - Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide - Google Patents
Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamideInfo
- Publication number
- SG10202010389TA SG10202010389TA SG10202010389TA SG10202010389TA SG10202010389TA SG 10202010389T A SG10202010389T A SG 10202010389TA SG 10202010389T A SG10202010389T A SG 10202010389TA SG 10202010389T A SG10202010389T A SG 10202010389TA SG 10202010389T A SG10202010389T A SG 10202010389TA
- Authority
- SG
- Singapore
- Prior art keywords
- methycyclohexylamino
- butylamino
- carboxamide
- pyrimidine
- tert
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092537P | 2014-12-16 | 2014-12-16 | |
US201562196044P | 2015-07-23 | 2015-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202010389TA true SG10202010389TA (en) | 2020-11-27 |
Family
ID=56110500
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704827UA SG11201704827UA (en) | 2014-12-16 | 2015-12-15 | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
SG10202010389TA SG10202010389TA (en) | 2014-12-16 | 2015-12-15 | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704827UA SG11201704827UA (en) | 2014-12-16 | 2015-12-15 | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
Country Status (19)
Country | Link |
---|---|
US (3) | US9796685B2 (zh) |
EP (2) | EP3712134B1 (zh) |
JP (2) | JP6762940B2 (zh) |
KR (1) | KR102606253B1 (zh) |
CN (2) | CN112451502B (zh) |
AU (2) | AU2015362728B2 (zh) |
BR (1) | BR112017012795A2 (zh) |
CA (2) | CA3210612A1 (zh) |
CL (1) | CL2017001545A1 (zh) |
CO (1) | CO2017006087A2 (zh) |
EA (1) | EA033530B1 (zh) |
EC (1) | ECSP17038150A (zh) |
ES (2) | ES2877642T3 (zh) |
IL (1) | IL252900B (zh) |
MX (2) | MX2017007883A (zh) |
NZ (1) | NZ732793A (zh) |
SA (1) | SA517381749B1 (zh) |
SG (2) | SG11201704827UA (zh) |
WO (1) | WO2016100310A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2699553T3 (pl) * | 2011-04-22 | 2024-03-25 | Signal Pharmaceuticals, Llc | Podstawione diaminokarboksyamido- i diaminokarbonitrylo-pirymidyny, ich kompozycje i sposoby leczenia nimi |
NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
JP6903577B2 (ja) * | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
BR112017012795A2 (pt) * | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
EP3325432B1 (en) | 2015-07-24 | 2020-09-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
DK3358347T3 (da) * | 2015-09-30 | 2020-11-30 | Univ Tohoku | Markør til bestemmelse af diabetisk nefropati |
KR20210029190A (ko) * | 2018-06-06 | 2021-03-15 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
KR20210029989A (ko) | 2019-09-09 | 2021-03-17 | 김경민 | 야구경기 데이터 기록 서버 및 야구경기 기록데이터 분석방법 |
CN112574123B (zh) * | 2019-09-30 | 2024-06-11 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
WO2024097940A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Therapy for the treatment of cancer |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
JP4135318B2 (ja) | 1997-12-15 | 2008-08-20 | アステラス製薬株式会社 | 新規なピリミジン−5−カルボキサミド誘導体 |
JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
PT1184376E (pt) | 1999-06-09 | 2005-04-29 | Yamanouchi Pharma Co Ltd | Novos derivados heterociclicos de carboxamida |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
SK3572002A3 (en) | 1999-08-13 | 2002-07-02 | Vertex Pharma | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003220968A1 (en) | 2002-03-28 | 2003-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
JPWO2004054617A1 (ja) | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および/または治療剤 |
WO2004067516A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
ES2424881T3 (es) | 2003-08-15 | 2013-10-09 | Novartis Ag | 2,4-Di(fenilamino)-pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmunitario |
CA2539235A1 (en) | 2003-09-24 | 2005-04-07 | Wyeth Holdings Corporation | 5-arylpyrimidines as anticancer agents |
JPWO2005095382A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
CA2579017A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Roflumilast and syk inhibitor combination and methods of use thereof |
CA2579007A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
BRPI0516748B8 (pt) | 2004-09-30 | 2021-05-25 | Janssen Sciences Ireland Uc | pirimidinas 5-substituídas inibidoras de hiv e composição farmacêutica que as compreende |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
EP2046759A1 (en) | 2006-07-21 | 2009-04-15 | Novartis AG | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
ES2593486T3 (es) | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
NZ581397A (en) | 2007-04-27 | 2012-02-24 | Astrazeneca Ab | Pyrimidine compounds for the inhibition of Eph receptors and for the treatment of cancer |
EP2183242A2 (en) | 2007-07-16 | 2010-05-12 | AstraZeneca AB | Pyrimidine derivatives 934 |
CA2693594A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
CN104230911A (zh) | 2008-04-16 | 2014-12-24 | 波托拉医药品公司 | 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物 |
JP5705720B2 (ja) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Sykまたはjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
CN102105150B (zh) | 2008-05-21 | 2014-03-12 | 阿里亚德医药股份有限公司 | 用作激酶抑制剂的磷衍生物 |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
MX357627B (es) | 2008-06-27 | 2018-07-17 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
WO2010024430A1 (ja) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-ジアミノピリミジン化合物 |
BRPI0918045A2 (pt) | 2008-09-18 | 2015-12-01 | Astellas Pharma Inc | compostos de carboxamida heterocíclicos |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
WO2010051223A1 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
WO2010068863A2 (en) * | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
JP5683489B2 (ja) | 2009-01-12 | 2015-03-11 | アレイ バイオファーマ、インコーポレイテッド | ピペリジン含有化合物およびその用途 |
EP2376481B1 (en) | 2009-01-13 | 2013-08-07 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
CA2749837C (en) | 2009-01-21 | 2017-07-11 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
RS57045B1 (sr) | 2009-05-08 | 2018-05-31 | Astellas Pharma Inc | Jedinjenje diamino heterocikličnog karboksamida |
MX2011013325A (es) | 2009-06-10 | 2012-04-30 | Abbott Lab | 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa. |
JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
US20130029967A1 (en) | 2009-09-24 | 2013-01-31 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors |
WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
WO2011068898A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
JP6035238B2 (ja) | 2010-07-21 | 2016-11-30 | ライジェル ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼc阻害剤およびその使用 |
US8580805B2 (en) | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
WO2012045020A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
PL2699553T3 (pl) * | 2011-04-22 | 2024-03-25 | Signal Pharmaceuticals, Llc | Podstawione diaminokarboksyamido- i diaminokarbonitrylo-pirymidyny, ich kompozycje i sposoby leczenia nimi |
NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
BR112017012795A2 (pt) * | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
-
2015
- 2015-12-15 BR BR112017012795-4A patent/BR112017012795A2/pt not_active Application Discontinuation
- 2015-12-15 EP EP20158407.5A patent/EP3712134B1/en active Active
- 2015-12-15 EA EA201791327A patent/EA033530B1/ru not_active IP Right Cessation
- 2015-12-15 US US14/969,750 patent/US9796685B2/en active Active
- 2015-12-15 ES ES15870856T patent/ES2877642T3/es active Active
- 2015-12-15 AU AU2015362728A patent/AU2015362728B2/en active Active
- 2015-12-15 ES ES20158407T patent/ES2972295T3/es active Active
- 2015-12-15 EP EP15870856.0A patent/EP3233809B1/en active Active
- 2015-12-15 SG SG11201704827UA patent/SG11201704827UA/en unknown
- 2015-12-15 SG SG10202010389TA patent/SG10202010389TA/en unknown
- 2015-12-15 MX MX2017007883A patent/MX2017007883A/es unknown
- 2015-12-15 JP JP2017532034A patent/JP6762940B2/ja active Active
- 2015-12-15 CN CN202011351088.3A patent/CN112451502B/zh active Active
- 2015-12-15 CN CN201580068532.1A patent/CN107108524A/zh active Pending
- 2015-12-15 WO PCT/US2015/065774 patent/WO2016100310A1/en active Application Filing
- 2015-12-15 KR KR1020177016285A patent/KR102606253B1/ko active IP Right Grant
- 2015-12-15 NZ NZ732793A patent/NZ732793A/en unknown
- 2015-12-15 CA CA3210612A patent/CA3210612A1/en active Pending
- 2015-12-15 CA CA2970926A patent/CA2970926C/en active Active
-
2017
- 2017-06-14 IL IL252900A patent/IL252900B/en unknown
- 2017-06-14 CL CL2017001545A patent/CL2017001545A1/es unknown
- 2017-06-15 MX MX2021005207A patent/MX2021005207A/es unknown
- 2017-06-15 SA SA517381749A patent/SA517381749B1/ar unknown
- 2017-06-19 EC ECIEPI201738150A patent/ECSP17038150A/es unknown
- 2017-06-20 CO CONC2017/0006087A patent/CO2017006087A2/es unknown
- 2017-09-18 US US15/707,047 patent/US10131639B2/en active Active
-
2018
- 2018-10-02 US US16/149,393 patent/US10590089B2/en active Active
-
2020
- 2020-05-22 JP JP2020089532A patent/JP7022172B2/ja active Active
- 2020-05-28 AU AU2020203497A patent/AU2020203497B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252900B (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
IL275305B (en) | Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them | |
EP3250557A4 (en) | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | |
ZA201701637B (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
IL270885A (en) | Compounds for the treatment of post-traumatic stress disorder | |
PL3348260T3 (pl) | Kompozycja farmaceutyczna tramadolu do zastosowania oftalmicznego | |
ZA201801496B (en) | Vlp stabilized vaccine compositions | |
SG11201707117SA (en) | Ophthalmic composition | |
EP3265177C0 (en) | FORMULATIONS OF HYDROPHILIC COMPOUNDS | |
EP3368517C0 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILM | |
EP3349853A4 (en) | PRODRUGS OF FENCAMFAMINE | |
HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
PT3142641T (pt) | Formulações para o tratamento de hipertiroidismo | |
EP3290049A4 (en) | Allergy vaccine composition | |
EP3212611A4 (en) | Crystal forms of verapamil hydrochloride | |
ZA201704927B (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use | |
GB201402377D0 (en) | Stable polymorph form B of tapentadol hydrochloride | |
PL3389638T3 (pl) | Kompozycja farmaceutyczna zawierająca pimobendan | |
GB201611619D0 (en) | Novel formulations of losartan | |
GB201611623D0 (en) | Novel formulations of losartan | |
GB201512635D0 (en) | Uses of therapeutic compounds | |
GB201504482D0 (en) | Novel formulations |